공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

궤양성 대장염 : 세계 의약품 예측과 시장 분석(-2029년)

Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029

리서치사 GlobalData
발행일 2020년 12월 상품 코드 980222
페이지 정보 영문 168 Pages
가격
US $ 10,995 ₩ 12,233,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 21,990 ₩ 24,466,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 32,985 ₩ 36,699,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


궤양성 대장염 : 세계 의약품 예측과 시장 분석(-2029년) Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2029
발행일 : 2020년 12월 페이지 정보 : 영문 168 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 궤양성 대장염(UC) 시장의 주요 성장요인으로 예측 기간 중 10건에 달하는 새로운 파이프라인 요법의 개시와 주요 8개국에서 진단된 증례 건수의 증가를 들 수 있습니다. 현재의 UC 시장은 경도로부터 중등도의 질환을 대상으로 한 저가 제네릭 의약품, TNF(anti-tumor necrosis factors) 및 항인테그린 등 고가의 바이오 제제, 중증 질환을 대상으로 한 단기 또는 장기 수술 대체품으로서 사용되는 바이오시밀러 등으로 과밀 상태입니다.

또한 이 시장의 성장에 대한 주요 장벽으로서 경쟁이 치열하고 혼잡한 시장뿐만 아니라 이후 바이오시밀러 발매에 수반하는 주요 바이오 브랜드의 특허 만료 등을 들 수 있습니다.

세계의 궤양성 대장염(UC) 시장에 대해 조사했으며, 역학, 병인, 병태생리학, 증상, 진단 및 치료 가이드라인을 포함한 UC의 개요, 시장 매출, 치료의 연간 비용 및 예측 기간의 주요 파이프라인 제품 판매량, 시장의 성장 및 억제요인 등의 정보를 정리하여 전해드립니다.

목차

제1장 목차

  • 표 리스트
  • 도표 리스트

제2장 궤양성 대장염 : 개요

  • 2019년-2029년 UC 시장의 대폭적인 성장 전망
  • 경쟁과 바이오시밀러의 위협에 의한 UC 시장의 정의
  • 파이프라인 제품에 의한 미충족 요구에 대한 부분적인 대응
  • 중증/전격성 환자를 관리할 기회
  • UC 시장의 성장을 촉진하기 위한 피하 바이오 제제 및 경구 요법
  • 의사와 지불자의 견해

제3장 서론

  • 영향
  • 관련 리포트
  • 향후 관련 리포트

제4장 질병의 개요

  • 병인과 병태생리학
  • 분류 또는 스테이징 시스템
  • 증상
  • 삶의 질

제5장 역학

  • 질병 배경
  • 위험인자와 병존 질환
  • 세계 및 과거 동향
  • 예측 조사 방법
  • UC의 역학 예측(2019-2029)
  • 토론

제6장 질병 관리

  • 진단과 치료의 개요
  • 치료의 개요
  • 치료 가이드라인과 주요 처방약
  • 미국
  • EU 5개국
  • 일본
  • 캐나다

제7장 경쟁 평가

  • 개요
  • COVID-19의 영향에 관한 KOL과 지불자의 견해

제8장 미충족 요구와 기회 평가

  • 개요
  • 안전하고 효과적인 대체 치료법의 결여
  • 중증/전격성 환자용 의료 관리의 개선
  • 치료와 예후에 대한 반응성을 예측하기 위한 바이오마커
  • 환자로부터 보고된 결과의 표준화

제9장 파이프라인 평가

  • 개요
  • 임상 개발에서의 유망 약제

제10장 현재 및 향후 기업

  • 개요
  • 기업 전략 동향
  • Johnson & Johnson
  • AbbVie
  • Takeda
  • Pfizer
  • Eli Lilly
  • EA Pharma
  • Galapagos
  • Bristol-Myers Squibb
  • Arena Pharmaceuticals

제11장 시장 전망

  • 세계 시장
  • 미국
  • EU 5개국
  • 일본
  • 캐나다

제12장 부록

  • 참고 문헌
  • 약어
  • 조사 방법
  • 1차 조사 : 본 보고서에서 인터뷰된 KOL과 지불자
  • 1차 조사 : 처방자 조사
  • 저자 소개
  • GlobalData 소개
  • 문의
  • 면책사항
KSA 21.01.14

List of Tables

List of Tables

  • Table 1: UC: Key Metrics in the 8MM
  • Table 2: Truelove and Witts Categorization of Disease Severity and Clinical Parameters
  • Table 3: Montreal Classification for the Distribution of UC
  • Table 4: Typical Symptoms of UC
  • Table 5: Risk Factors and Comorbidities for UC and IBD
  • Table 6: Guidelines Used for Managing UC
  • Table 7: Country Profile - US
  • Table 8: Country Profile - 5EU
  • Table 9: Country Profile - Japan
  • Table 10: Country Profile - Canada
  • Table 11: Leading Treatments for UC, 2020
  • Table 12: Johnson & Johnson's Disease Portfolio Assessment, 2020
  • Table 13: AbbVie's Disease Portfolio Assessment, 2020
  • Table 14: Takeda's Disease Portfolio Assessment, 2020
  • Table 15: Pfizer's Disease Portfolio Assessment, 2020
  • Table 16: Eli Lilly's Disease Portfolio Assessment, 2020
  • Table 17: EA Pharma's Disease Portfolio Assessment, 2020
  • Table 18: Galapagos' Disease Portfolio Assessment, 2020
  • Table 19: Bristol-Myers Squibb's Disease Portfolio Assessment, 2019
  • Table 20: Arena's Disease Portfolio Assessment, 2020
  • Table 21: Disease UC Market - Global Drivers and Barriers, 2019-2029
  • Table 22: Key Events Impacting Sales for Disease UC in the US, 2019-2029
  • Table 23: Disease UC Market - Drivers and Barriers in the US, 2019-2029
  • Table 24: Key Events Impacting Sales for Disease UC in the 5EU, 2019-2029
  • Table 25: Disease UC Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 26: Key Events Impacting Sales for Disease UC in Japan, 2019-2029
  • Table 27: Disease UC Market - Drivers and Barriers in Japan, 2019-2029
  • Table 28: Key Events Impacting Sales for Disease UC in Canada, 2019-2029
  • Table 29: UC Market -Drivers and Barriers in Canada, 2019-2029
  • Table 30: Key Historical and Projected Launch Dates for UC
  • Table 31: Key Historical and Projected Patent Expiry Dates for UC
  • Table 32: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Ulcerative Colitis in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in UC During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period
  • Figure 4: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 5: Types of UC
  • Figure 6: 8MM, Diagnosed Incidence of UC, Men and Women, Cases per 100,000 Population, All Ages, 2019
  • Figure 7: 8MM, Diagnosed Prevalence of UC, Men and Women, %, All Ages, 2019
  • Figure 8: 8MM, Total Prevalence of UC, Men and Women, %, All Ages, 2019
  • Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of UC
  • Figure 10: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of UC
  • Figure 11: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of UC
  • Figure 12: 8MM, Sources Used to Forecast the Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC
  • Figure 13: 8MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of UC for Ages <18 years
  • Figure 14: 8MM, Diagnosed Incident Cases of UC, N, Both Sexes, All Ages, 2019
  • Figure 15: 8MM, Diagnosed Incident Cases of UC by Age, N, Both Sexes, 2019
  • Figure 16: 8MM, Diagnosed Incident Cases of UC by Sex, N, All Ages, 2019
  • Figure 17: 8MM, Diagnosed Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
  • Figure 18: 8MM, Diagnosed Prevalent Cases of UC by Age, N, Both Sexes, 2019
  • Figure 19: 8MM, Diagnosed Prevalent Cases of UC by Sex, N, All Ages, 2019
  • Figure 20: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages <18 years, 2019
  • Figure 21: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages ≥18 Years, 2019
  • Figure 22: 8MM, Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC, 2019
  • Figure 23: 8MM, Total Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
  • Figure 24: 8MM, Total Prevalent Cases of UC by Age, N, Both Sexes, 2019
  • Figure 25: 8MM, Total Prevalent Cases of UC by Sex, N, All Ages, 2019
  • Figure 26: UC Treatment Algorithm
  • Figure 27: Unmet Need and Opportunity in UC, 2020
  • Figure 28: Overview of the Development Pipeline in UC
  • Figure 29: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for UC in the 8MM During the Forecast Period
  • Figure 30: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period
  • Figure 31: Analysis of the Company Portfolio Gap in UC During the Forecast Period
  • Figure 32: Global (8MM) Sales Forecast by Country for UC in 2019 and 2029
  • Figure 33: Global (8MM) Sales Forecast by Class for UC in 2019 and 2029
  • Figure 34: Sales Forecast by Class for UC in the US in 2019 and 2029
  • Figure 35: Sales Forecast by Class for UC in the 5EU in 2019 and 2029
  • Figure 36: Sales Forecast by Class for UC in Japan in 2019 and 2029
  • Figure 37: Sales Forecast by Class for UC in Canada in 2019 and 2029

Ulcerative colitis (UC) is a type of inflammatory bowel disease. In UC, chronic inflammation affects the colon (also known as the large intestines). Initially, UC usually manifests in the terminal part of the colon, the rectum, and is termed ulcerative proctitis. It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis). The current UC market is overcrowded with cheap generic drugs for mild to moderate disease, expensive biologics such as anti-tumor necrosis factors (TNFs) and anti-integrins, and biosimilars for severe disease that are used as short- or long-term alternatives to surgical options. The R&D within this space consists of 10 late-stage pipeline drugs with five oral formulations, more convenient dosing frequencies, novel mechanisms of action (MOAs), and improved safety profiles and drug availability. However, the pipeline products will be challenged by the increasing emergence of biosimilars, since the major brands will experience patent cliffs throughout the forecast period. Furthermore, all but one drug are being developed for moderate to severe UC, which will result in a crowded market.

This model covers the market forecast for the marketed and late-stage pipeline UC therapeutics. The model segments patients by severity, with mild-moderate, moderate-severe, and severe/fulminant segments. The base year of this model is 2019, and the forecast period is 2020-2029.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of ulcerative colitis in the 8MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for ulcerative colitis? How should these strategies differ across different geographical markets?
  • What effect will the launch of biosimilars and generics have on the sales of branded agents?
  • What are the main R&D trends in the ulcerative colitis market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Key Highlights

  • The greatest drivers of growth in the global UC market include the launch of 10 new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 8MM countries.
  • The main barriers to growth in the UC market include the crowded and competitive market as well as patent expiration of key biologic brands with subsequent biosimilar launch.
  • Novel drug classes in the UC pipeline include IL-23 inhibitors and S1P receptor modulators. In addition, Takeda will launch a subcutaneous version of their product, Entyvio, and two additional JAK inhibitors are expected to make their appearance on the market.
  • The most important unmet needs in the UC market are for safer and more effective therapies, an improvement in management of fulminant patients, biomarkers to predict responsiveness to therapy, and standardization of patient-reported outcomes.

Scope

  • Overview of UC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline UC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global UC therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Ulcerative Colitis: Executive Summary

  • 2.1 Large Growth is Expected for UC Market from 2019-2029
  • 2.2 Competition and Biosimilar Threat Defines UC Market
  • 2.3 Pipeline Products Partially Address Unmet Needs
  • 2.4 Opportunities for Managing Severe/Fulminant Patients Remain
  • 2.5 Subcutaneous Biologics and Oral Therapies to Drive Growth in UC Market
  • 2.6 What Do Physicians and Payers Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Symptoms
  • 4.4 Quality of Life

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
  • 5.5 Epidemiological Forecast for UC (2019-2029)
  • 5.6 Discussion

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 Treatment Overview
  • 6.3 Treatment Guidelines and Leading Prescribed Drugs
  • 6.4 US
  • 6.5 5EU
  • 6.6 Japan
  • 6.7 Canada

7 Competitive Assessment

  • 7.1 Overview
  • 7.2 KOL and Payer Opinion on the Impact of COVID-19

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Lack of Safe and Efficacious Treatment Alternatives
  • 8.3 Improved Medical Management for Severe/Fulminant Patients
  • 8.4 Biomarkers to Predict Responsiveness to Therapy and Prognosis
  • 8.5 Standardization of Patient-Reported Outcomes

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Johnson & Johnson
  • 10.4 AbbVie
  • 10.5 Takeda
  • 10.6 Pfizer
  • 10.7 Eli Lilly
  • 10.8 EA Pharma
  • 10.9 Galapagos
  • 10.10 Bristol-Myers Squibb
  • 10.11 Arena Pharmaceuticals

11 Market Outlook

  • 11.1 Global Markets
  • 11.2 US
  • 11.3 5EU
  • 11.4 Japan
  • 11.5 Canada

12 Appendix

  • 12.1 Bibliography
  • 12.2 Abbreviations
  • 12.3 Methodology
  • 12.4 Primary Research - KOLs and Payers Interviewed for This Report
  • 12.5 Primary Research - Prescriber Survey
  • 12.6 About the Authors
  • 12.7 About GlobalData
  • 12.8 Contact Us
  • 12.9 Disclaimer
Back to Top
전화 문의
F A Q